133482Small molecule activators of cAMP PDE4 long isoforms for immuno-oncologyClosedFeasibility StudiesInnovate UKAccording to the World Health Organisation 8.8 million people died of cancer in 2015: 1 in 6 of all global deaths. Tumours are able to hide from the immune system, avoiding detection and removal by the body's natural defences. The ability to reveal tumours to the immune system by overcoming cloaking processes, the core of immuno-oncology, is showing great promise in the treatment of cancer. Mironid is applying its unique understanding of cAMP signalling to develop a pioneering approach to immuno-oncology. cAMP signalling within cells is compartmentalised and its elevation in a compartment controlled by cAMP phosphodiesterase-4 (PDE4), which degrades cAMP, and attenuates immune system function. cAMP is a key molecule involved in cell signalling and excessive levels of cAMP can prevent the immune system from attacking tumour cells. Mironid have developed, for the first time, compounds that activate PDE4\. This enhances cAMP degradation in this key compartment removing the brake that holds the immune system back from attacking tumours. We will evaluate PDE4 activators as novel agents for stimulating the immune system to attack tumours. This innovative programme provides an excellent opportunity to improve the effectiveness of cancer treatment and save lives. Sustainable economic impact will be achieved by establishing Mironid as a leading UK pharma company with long term growth prospects and employment benefits.